Table 1– Patient characteristics at baseline and 3–12 months after treatment initiation
VariablesPatients with full data available nBaseline valuesValues at first invasive follow-up 3–12 months after initiation of therapyp-value
Age yrs10955 (42–68)
Female %10978
WHO functional class1003±0.63±0.40.41
6-MWD m95358 (300–432)399 (330–450)0.001
RA pressure mmHg1097 (3–11)7 (3–11)0.88
pa mmHg10952 (44–60)52 (45–60)0.55
Cardiac index L·min−1·m−21092.0 (1.7–2.6)2.2 (1.8–2.8)<0.001
PVR dyn·sec·cm−5103961 (675–1257)940 (601–1188)0.68
Sv,O2 %10962 (56–68)63 (55–69)0.85
SVI mL·m2·beat−18227.9 (21–33)26.3 (19–37)0.002
Capacitance mL·mmHg−1731.1 (0.7–1.2)1.3 (0.8–1.7)0.06
NT-proBNP ng·L−1841292 (300–3510)1177 (474–2920)0.02
Bilirubin μmol·L−11031516 (9–25)0.14
γGT U·L−110447 (24–95)56 (31–113)0.11
Creatinine μmol·L−110580 (68–96)80 (67–100)0.67
BUN mmol·L−11056.0 (4.7–7.5)6.2 (4.5–7.5)0.79
Uric acid μmol·L−1104403 (321–521)396 (309–487)0.26
CRP mg·L−1835 (3–6)5 (3–8)0.03
RDW %10414.9 (13.7–16.1)15.2 (14.2–17.1)0.16
S-Na+ mmol·L−1100139.7 (138–142)140.6 (139–143)0.03
  • Data are presented as median (interquartile range) or mean±sd, unless otherwise stated. WHO: World Health Organization; 6-MWD: 6-min walk distance; RA: right atrial; pa: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; Sv,O2: mixed-venous oxygen saturation; SVI: stroke volume index; NT-proBNP: N-terminal pro-brain natriuretic peptide; γGT: gamma-glutamyltransferase; BUN: blood urea nitrogen; CRP: C-reactive protein; RDW: red cell distribution width; S-Na+: serum sodium level.